There�s promising news for women with the most serious form of ovarian cancer. 

Ovarian cancer that has spread or returned after paclitaxel and platinum-based chemotherapy is one of the deadliest forms of gynecologic cancer.  Now, women fighting this type of cancer have another treatment option.  A medication called Doxil^�, also known as doxorubicin hyrochloride liposome injection, uses a special �stealth� technology.  Ovarian cancer specialist, Doctor Alan Gordon led a recent clinical trial to study the drug:

�The �stealth� technology is designed to protect the medication by preventing the body from breaking down the active agent.  That allows the medication to circulate in the blood longer, and allows it to be given once a month.�

Education is essential in fighting ovarian cancer, as symptoms often do not occur until the cancer spreads.  For information about doxil� and symptoms and risk factors for ovarian cancer, visit doxil-dot-com.  Talk to your doctor if you have questions.

Doxil� is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel and platinum-based chemotherapy regimens.  Refractory disease is defined as disease that has progressed while on treatment, or within six months of completing treatment. This indication is based on objective tumor response rates.  No results are available from controlled studies that demonstrate a clinical benefit resulting from this treatment, such as improvement in disease-related symptoms or increased survival.

CLICK HERE to download a transcript of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/ovary.doc

CLICK HERE to download a multimedia (MP3) file of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/ovary.mp3